Influence of patient preferences on the cost-effectiveness of screening for Lynch syndrome

American Journal of Managed Care

Volumn 18, Issue 5, 2012, Pages

  Wang, Grace ^a,b   Kuppermann, Miriam ^b   Kim, Benjamin ^b   Phillips, Kathryn A ^b   Ladabaum, Uri ^c  

^a AMERICAN INSTITUTES FOR RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE;

ADULT; ARTICLE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; GENE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; MEDICARE; PATIENT PREFERENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RISK REDUCTION; SENSITIVITY ANALYSIS;

COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; CONFIDENCE INTERVALS; COST-BENEFIT ANALYSIS; HUMANS; MASS SCREENING; PATIENT SATISFACTION; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES;

EID: 84864417520     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Vasen HF, Möslein G, Alonso A, et al: Recommendations to improve identification of hereditary and familial colorectal cancer in Europe. Fam Cancer 9:109-115, 2010
2. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group: Recommendations from the EGAPP Working Group: Genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 11:35-41, 2009
3. Dinh TA, Rosner BI, Atwood JC, et al: Health benefits and costeffectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila) 4:9-22, 2011
4. Ladabaum U, Wang G, Terdiman J, et al: Strategies to identify the Lynch syndrome among patients with colorectal cancer: A cost-effectiveness analysis. Ann Intern Med 155:69-79, 2011
5. Gudgeon JM, Williams JL, Burt RW, et al: Lynch syndrome screening implementation: Business analysis by a healthcare system. Am J Manag Care 17:e288-e300, 2011
6. Mvundura M, Grosse SD, Hampel H, et al: The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med 12:93-104, 2010
7. Stupart DA, Goldberg PA, Algar U, et al: Surveillance colonoscopy improves survival in a cohort of subjects with a single mismatch repair gene mutation. Colorectal Dis 11:126-130, 2009
8. Jarvinen HJ, Aarnio M, Mustonen H, et al: Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118:829-834, 2000 (Pubitemid 30243745)
9. Koornstra JJ, Mourits MJ, Sijmons RH, et al: Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol 10:400-408, 2009
10. Claes E, Denayer L, Evers-Kiebooms G, et al: Predictive testing for hereditary nonpolyposis colorectal cancer: Subjective perception regarding colorectal and endometrial cancer, distress, and health-related behavior at one year post-test. Genet Test 9:54-65, 2005 (Pubitemid 40586431)
11. Hadley DW, Ashida S, Jenkins JF, et al: Colonoscopy use following mutation detection in Lynch syndrome: Exploring a role for cancer screening in adaptation. Clin Genet 79:321-328, 2011
12. Umar A, Boland CR, Terdiman JP, et al: Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96:261-268, 2004 (Pubitemid 38256271)
13. Vasen HF, Watson P, Mecklin JP, et al: New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116:1453-1456, 1999 (Pubitemid 29258894)
14. Barnetson RA, Tenesa A, Farrington SM, et al: Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 354:2751-2763, 2006 (Pubitemid 43974193)
15. Balmana J, Balaguer F, Castellvi-Bel S, et al: Comparison of predictive models, clinical criteria and molecular tumour screening for the identification of patients with Lynch syndrome in a population-based cohort of colorectal cancer patients. J Med Genet 45:557-563, 2008
16. Kastrinos F, Steyerberg EW, Mercado R, et al: The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology 140:73-81, 2011
17. Green RC, Parfrey PS, Woods MO, et al: Prediction of Lynch syndrome in consecutive patients with colorectal cancer. J Natl Cancer Inst 101:331-340, 2009
18. Martin SA, Lord CJ, Ashworth A: Therapeutic targeting of the DNA mismatch repair pathway. Clin Cancer Res 16:5107-5113, 2010
19. Shia J: Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: Part I - The utility of immunohistochemistry. J Mol Diagn 10:293-300, 2008
20. Locker GY, Hamilton S, Harris J, et al: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24:5313-5327, 2006 (Pubitemid 46631379)
21. Boland CR, Thibodeau SN, Hamilton SR, et al: A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58:5248-5257, 1998
22. Zhang L: Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: Part II - The utility of microsatellite instability testing. J Mol Diagn 10:301-307, 2008
23. US Preventive Services Task Force Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 149:627-637, 2008
24. Boland CR, Goel A: Microsatellite instability in colorectal cancer. Gastroenterology 138:2073-2087, 2010
25. Kuppermann M, Wang G, Wong S, et al: Preferences for outcomes associated with decisions to undergo or forego genetic testing for Lynch syndrome. Cancer (in press)
26. Aktan-Collan K, Haukkala A, Mecklin JP, et al: Psychological consequences of predictive genetic testing for hereditary non-polyposis colorectal cancer (HNPCC): A prospective follow-up study. Int J Cancer 93:608-611, 2001 (Pubitemid 32701422)
27. Collins VR, Meiser B, Ukoumunne OC, et al: The impact of predictive genetic testing for hereditary nonpolyposis colorectal cancer: Three years after testing. Genet Med 9:290-297, 2007 (Pubitemid 46788195)
28. Gritz ER, Peterson SK, Vernon SW, et al: Psychological impact of genetic testing for hereditary nonpolyposis colorectal cancer. J Clin Oncol 23:1902-1910, 2005 (Pubitemid 46211368)
29. Shiloh S, Koehly L, Jenkins J, et al: Monitoring coping style moderates emotional reactions to genetic testing for hereditary nonpolyposis colorectal cancer: A longitudinal study. Psychooncology 17:746-755, 2008
30. Claes E, Evers-Kiebooms G, Decruyenaere M, et al: Surveillance behavior and prophylactic surgery after predictive testing for hereditary breast/ovarian cancer. Behav Med 31:93-105, 2005 (Pubitemid 41476567)
31. Keller M, Jost R, Haunstetter CM, et al: Psychosocial outcome following genetic risk counselling for familial colorectal cancer: A comparison of affected patients and family members. Clin Genet 74:414-424, 2008
32. Meiser B, Collins V, Warren R, et al: Psychological impact of genetic testing for hereditary non-polyposis colorectal cancer. Clin Genet 66:502-511, 2004 (Pubitemid 39562012)
33. Keller M, Jost R, Haunstetter CM, et al: Comprehensive genetic counseling for families at risk for HNPCC: Impact on distress and perceptions. Genet Test 6:291-302, 2002 (Pubitemid 36020053)
34. Hasenbring MI, Kreddig N, Deges G, et al: Psychological impact of genetic counseling for hereditary nonpolyposis colorectal cancer: The role of cancer history, gender, age, and psychological distress. Genet Test Mol Biomarkers 15:219-225, 2011
35. Holland ML, Huston A, Noyes K: Cost-effectiveness of testing for breast cancer susceptibility genes. Value Health 12:207-216, 2009
36. Kwon JS, Sun CC, Peterson SK, et al: Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome. Cancer 113:326-335, 2008
37. Fryback DG, Lawrence WF, Martin PA, et al: Predicting quality of well-being scores from the SF-36: Results from the Beaver Dam Health Outcomes Study. Med Decis Making 17:1-9, 1997 (Pubitemid 27020134)
38. Palomaki GE, McClain MR, Melillo S, et al: EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 11:42-65, 2009
39. Horner MJ, Ries LAG, Krapcho M, et al (eds): SEER cancer statistics review, 1975-2006. http://seer.cancer.gov/csr/1975-2006
40. US Department of Labor, Bureau of Labor Statistics: Consumer price index. http://www.bls.gov/cpi
41. The Ohio State University: OSU James screening for hereditary colon cancer syndrome. http://www.internalmedicine.osu.edu/nephrology/article.cfm?ID= 3068
42. Briggs A, Claxton K, Sculpher M: Making decision models probabilistic, in Decision Modelling for Health Economic Evaluation. Cambridge, MA, Oxford University Press, 2006, pp 77-120
43. Hillner BE, Schrag D, Sargent DJ, et al: Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma. Cancer 104:1871-1884, 2005 (Pubitemid 41513170)
44. Hadley DW, Jenkins J, Dimond E, et al: Genetic counseling and testing in families with hereditary nonpolyposis colorectal cancer. Arch Intern Med 163:573-582, 2003 n